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Abstract
Myostatin (Mstn) is a secreted growth factor expressed in skeletal muscle and adipose tissue that negatively regulates
skeletal muscle mass. Mstn
2/2 mice have a dramatic increase in muscle mass, reduction in fat mass, and resistance to diet-
induced and genetic obesity. To determine how Mstn deletion causes reduced adiposity and resistance to obesity, we
analyzed substrate utilization and insulin sensitivity in Mstn
2/2 mice fed a standard chow. Despite reduced lipid oxidation in
skeletal muscle, Mstn
2/2 mice had no change in the rate of whole body lipid oxidation. In contrast, Mstn
2/2 mice had
increased glucose utilization and insulin sensitivity as measured by indirect calorimetry, glucose and insulin tolerance tests,
and hyperinsulinemic-euglycemic clamp. To determine whether these metabolic effects were due primarily to the loss of
myostatin signaling in muscle or adipose tissue, we compared two transgenic mouse lines carrying a dominant negative
activin IIB receptor expressed specifically in adipocytes or skeletal muscle. We found that inhibition of myostatin signaling in
adipose tissue had no effect on body composition, weight gain, or glucose and insulin tolerance in mice fed a standard diet
or a high-fat diet. In contrast, inhibition of myostatin signaling in skeletal muscle, like Mstn deletion, resulted in increased
lean mass, decreased fat mass, improved glucose metabolism on standard and high-fat diets, and resistance to diet-induced
obesity. Our results demonstrate that Mstn
2/2 mice have an increase in insulin sensitivity and glucose uptake, and that the
reduction in adipose tissue mass in Mstn
2/2 mice is an indirect result of metabolic changes in skeletal muscle. These data
suggest that increasing muscle mass by administration of myostatin antagonists may be a promising therapeutic target for
treating patients with obesity or diabetes.
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Introduction
Myostatin (Mstn), a member of the transforming growth factor
b (TGFb) superfamily of secreted growth factors, is an important
regulator of skeletal muscle development and adult homeostasis.
Mstn is strongly expressed in skeletal muscle and Mstn
2/2 mice
have a great increase in muscle mass demonstrating that myostatin
is a muscle-specific negative regulator of skeletal muscle size [1,2].
Mutations in the Mstn gene in cattle, sheep, dogs, and one child
cause an increase in skeletal muscle mass indicating conservation
of function in mammals [3]. Myostatin also regulates muscle mass
in adult mice: Inhibition of myostatin by injection of neutralizing
antibodies or antagonists causes an increase in skeletal muscle
mass in both healthy adult mice and in mouse models of muscular
dystrophy [4,5,6,7,8,9,10,11]. Myostatin inhibitors have therefore
generated great interest as candidates for treatment of muscle
wasting diseases.
The myostatin protein is synthesized as a full-length precursor that
is cleaved into an amino-terminal pro-peptide and a carboxy-
terminal mature region which is the active form of the molecule. In
skeletal muscle and in circulation, myostatin is found in inactive
complexes of differing composition with other proteins such as its own
pro-peptide, follistatin-like 3 (Fstl3, also known as follistatin-related
gene),and latent TGFbbindingprotein[1,12,13].Themechanismof
activation of these inactive complexes or whether all of these
complexes are capable of being activated is unknown. For complexes
containing the pro-peptide, activation likely requires proteolysis of the
pro-peptide, perhaps by specific target cells [11,14]. Once activated,
myostatin has high affinity for the activin IIB receptor (Acvr2b, also
known as ActRIIB) and weak affinity for Acvr2a (also known as
ActRII and ActRIIA), both of which, like other receptors for TGFb
family members, bind multiple ligands [15].
The effects of Mstn deletion are not restricted to skeletal muscle.
Many skeletal muscles of Mstn
2/2 mice are twice the mass of those
of Mstn
+/+ mice [16] while, in contrast, adipose tissue is greatly
reduced in size [17,18]. Deletion of Mstn in genetic mouse models
of obesity and diabetes improves obesity and glucose metabolism
[18], and Mstn
2/2 mice in a CD-1 genetic background are
resistant to weight gain due to diet-induced obesity [19].
Furthermore, transgenic mice overexpressing the secreted myos-
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and are resistant to both weight gain and the development of
insulin resistance when fed a high-fat diet (HFD) although these
mice do not have reduced adiposity or improved insulin sensitivity
when fed a standard diet [20].
The Mstn gene is expressed at low levels in adipose tissue and
myostatin protein is found in circulation suggesting that myostatin
could have a direct role in regulating adipocyte differentiation or
function [1]. In vitro, myostatin promotes adipogenesis in the
multipotential C3H 10T1/2 mesenchymal cell line [21,22] and
inhibits adipogenesis in 3T3L1 preadipocytes [23,24] indicating
that myostatin actions are different during determination and
differentiation steps. In vivo, Mstn overexpression in adipose tissue
results in small immature adipocytes, increased energy expendi-
ture, and resistance to diet-induced obesity [22]. Furthermore, the
expression of Mstn, Fstl3, and Acvr2b is upregulated in adipocytes
from obese mice suggesting myostatin signaling may play a role in
the response of adipocytes to obesity [25].
Whether myostatin directly regulates the overall mass of adipose
tissue as it does skeletal muscle, however, is unclear. Experiments
using direct injection of myostatin protein have produced
conflicting results in regard to the effect on fat mass [24,26].
Transgenic mice overexpressing Mstn specifically in adipose tissue
have normal body composition despite a reduction in adipocyte
size [22]. In contrast, high systemic levels of myostatin or deletion
of the antagonist Fstl3 cause a loss of adipose tissue mass [24,27].
Several other transgenic mouse models that have increased
muscle mass, including some using muscle-specific promoters to
drive expression of genes that cause muscle hypertrophy, also have
decreased adiposity demonstrating that changes in adipose tissue
size can be indirectly caused by changes in skeletal muscle size
[28,29,30,31]. For example, HFD-fed mice expressing a muscle-
specific inducible constitutively active Akt1 transgene lose body
and adipose tissue weight after muscle hypertrophy is induced
[29]. Thus, a role for myostatin in regulating adipose tissue mass
directly cannot be determined by analysis of the extremely
muscular Mstn
2/2 mouse.
Here, we asked what metabolic changes cause the reduced
adiposity and resistance to obesity in Mstn
2/2 mice. We then
determined whether these changes were mediated by the loss of
direct myostatin signaling in adipose tissue, or whether the altered
metabolism is due to the loss of myostatin signaling in skeletal
muscle.
Results
Altered substrate utilization in Mstn
2/2 mice
One possible explanation for a decrease in adiposity is an
increase in metabolic rate. It has been previously shown that
Mstn
2/2 mice have a slightly higher metabolic rate per animal and
slightly lower metabolic rate normalized to total body weight [18].
We reexamined oxygen consumption in Mstn
2/2 mice fed a
standard diet and normalized the data to lean mass. Our results
confirmed that Mstn
2/2 mice have a lower metabolic rate when
normalized to lean mass or to total body weight (Table S1).
Additionally, Mstn
2/2 mice had no change in total or ambulatory
activity (Table S1). Thus, the improved glucose metabolism in
Mstn
2/2 mice does not appear to be caused by an increase in
metabolic rate or activity.
We also determined the respiratory exchange ratio (RER) in fed
mice by indirect calorimetry. The RER is a measure of the ratio of
the volume of CO2 produced to the volume of O2 consumed by an
animal which reflects the relative oxidation of carbohydrates to
lipids. The RER in fed Mstn
2/2 mice was significantly higher than
in Mstn
+/+ mice suggesting the mutant mice have increased
carbohydrate utilization, reduced lipid utilization, or both (Fig. 1A).
To determine whether Mstn
2/2 mice fed standard chow had a
change in the utilization of lipid, we measured fatty acid oxidation
rates in whole animals and in soleus muscle. The rate of fatty acid
oxidation per animal was not significantly different between
Figure 1. Substrate utilization in Mstn
+/+ and Mstn
2/2 mice on standard chow. (A) Total respiratory exchange ratio determined by indirect
calorimetry. (B) Amount of palmitate oxidized per soleus muscle. (C) Amount of palmitate oxidized by soleus muscle normalized to soleus mass. (D)
Rate of oleic acid oxidation per mouse. (E) Rate of oleic acid oxidation normalized to lean mass. n=6–10. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0004937.g001
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2/2 mice had significantly lower rates of
fatty acid oxidation compared to Mstn
+/+ mice, however, after
normalization to lean mass (Fig. 1E). This difference was also seen
in isolated soleus muscle. The rate of fatty acid oxidation was not
different per muscle (Fig. 1B), but was significantly lower in Mstn
2/
2 soleus muscle normalized to muscle mass (Fig. 1C). These results
suggest that the increase in RER in Mstn
2/2 mice is due to
increased carbohydrate utilization for energy while overall lipid
utilization per animal is unchanged.
Glucose metabolism in Mstn
2/2 mice
The decreased adiposity and increased carbohydrate utilization
in Mstn
2/2 mice suggest they may have altered glucose
metabolism. As previously reported [18], fed and fasting glucose
and fed insulin levels in Mstn
2/2 mice were not significantly
different from controls although insulin tended to be lower
(P=0.067) (Table 1). To examine the response to exogenous
glucose, we performed glucose tolerance tests (GTT) on mice fed
standard chow. Mstn
2/2 mice had significantly improved glucose
tolerance compared to Mstn
+/+ littermates (Fig. 2A). To determine
whether the reduced glucose levels in response to exogenous
glucose load were due to higher insulin secretion, we measured
serum insulin at 0 and 30 minutes after glucose injection in fasted
mice. Fasting blood glucose and serum insulin levels were lower in
Mstn
2/2 mice compared to Mstn
+/+ mice 30 minutes after glucose
injection suggesting that the improvement in the GTT was due to
increased response to insulin rather than to increased insulin
secretion (Fig. 2C). We therefore performed insulin tolerance tests
(ITT) to measure blood glucose changes after insulin administra-
tion. Mstn
2/2 mice had lower blood glucose levels than Mstn
+/+
littermates after insulin injection demonstrating improved insulin
tolerance (Fig. 2B).
Response to high-fat diet
We determined whether this improvement in glucose metabo-
lism was maintained in Mstn
2/2 mice fed a HFD. Mice were fed a
HFD for 10 weeks and compared to age-matched littermates fed
standard chow. Food intake as a function of body weight was not
different between genotypes on HFD (data not shown). As
expected, Mstn
2/2 mice gained significantly less weight than
Mstn
+/+ controls on a HFD over the 10 week interval (Fig. 2D).
Unlike Mstn
+/+ mice, Mstn
2/2 mice gained the same amount of
body weight on HFD as they did on standard chow over the same
time period. Mstn
2/2 mice, however, were not completely
resistant to the effects of diet-induced obesity. Mstn
2/2 mice fed
a HFD had increased fat pad mass (Fig. S1) and larger adipocytes
(Fig. S2) compared to Mstn
2/2 mice fed a standard diet. The
weights of individual muscles, in contrast, were unaffected by diet
(data not shown).
A HFD caused glucose intolerance in both genotypes relative to
their response on standard chow (Fig. 2A). Similar to the results
from mice fed a standard chow, however, Mstn
2/2 mice on HFD
had better glucose tolerance compared to Mstn
+/+ mice on HFD
(Fig. 2A). Mstn
2/2 mice also had better insulin tolerance on HFD
compared to Mstn
+/+ mice (Fig. 2B). Fed and fasting glucose in
Mstn
2/2 mice were not significantly different from controls fed a
Table 1. Serum chemistry from mice on standard chow and HFD.
Fed glucose
(mg/dl)
Fasting glucose
(mg/dl)
Insulin
(pmol/L)
Resistin
(ng/ml)
Leptin
(ng/mL)
Free fatty
acids (mM)
Triglyceride
(mg/dl)
Standard Chow
Mstn
+/+ 14265 10267 544698 3.7860.14 24.6061.32 0.32360.040 65.365.2
Mstn
2/2 140698 7 65 103634 3.4860.13 1.9660.57
{{ 0.21960.022 41.163.7**
HFD
Mstn
+/+ 14365 12666
{ 884696
{ 4.7960.29* 28.3461.72 0.30060.020 51.865.6
Mstn
2/2 14067 10968* 177650
{{ 3.7260.26 17.2863.40
{ 0.25260.034 40.363.3
Standard Chow
Non-tg 140659 5 63 3326110 3.3660.08 10.4762.20 0.47960.069 61.765.4
Muscle-DN 124648 1 646 0 69 3.1060.20 0.3460.20 0.22260.026
{{ 35.762.5**
HFD
Non-tg 13664 113610* 6766107* 4.8460.50
{ 18.1263.56 0.43160.052 44.564.5*
Muscle-DN 124658 9 66 182650
{{ 3.5960.14 2.3560.99** 0.27160.037 33.663.9
Standard Chow
Non-tg. 142658 3 63 346691 3.7960.18 10.0665.81 0.37860.059 52.568.7
Fat-DN 14667 104610 136621 4.8260.12 16.3763.92 0.18160.017
{{ 44.465.1
HFD
Non-tg 180612
{ 14466
{ 6526120* 5.9460.31
{ 24.4264.23
{ 0.28660.034 46.669.8
Fat-DN 16765* 11567 5136139
{ 8.1060.76
{,{{ 23.3964.48 0.19960.019 40.563.3
Data are expressed as mean6SEM of 5–17 per group.
*P,0.05.
{P,0.01.
{P,0.001 vs. same genotype on standard chow.
**P,0.05.
{{P,0.01.
{{P,0.001 vs. control on the same diet.
Non-tg, non-transgenic controls.
doi:10.1371/journal.pone.0004937.t001
Mstn Inhibition and Metabolism
PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4937HFD (Table 1). Serum insulin was significantly lower in Mstn
2/2
mice fed a HFD demonstrating that less insulin was required to
maintain normal glycemia compared to Mstn
+/+ mice (Table 1).
To determine whether other circulating molecules relevant to
metabolism were affected by Mstn deletion in mice on either diet,
we measured levels of free fatty acids (FFA), triglycerides, and the
adipokines leptin and resistin. Serum triglycerides were signifi-
cantly lower in Mstn
2/2 mice than in Mstn
+/+ mice on standard
chow while FFA levels were normal (Table 1). As previously
reported [18], serum leptin was significantly lower in Mstn
2/2
mice on standard chow than in controls. Serum resistin levels were
normal. On HFD, the levels of FFA, triglycerides, leptin, and
resistin were not significantly different between Mstn
+/+ and
Mstn
2/2 mice. Liver triglyceride concentrations were also
significantly lower in Mstn
2/2 mice on both diets (Table S2).
Insulin sensitivity in Mstn
2/2 mice
The improvement in glucose and insulin tolerance, reduction in
serum insulin levels, and decrease in adipose mass in Mstn
2/2
mice suggest that these mice have increased insulin sensitivity
relative to Mstn
+/+ mice even on standard chow. To determine
whether Mstn
2/2 mice have higher glucose uptake than Mstn
+/+
mice, we carried out a hyperinsulinemic-euglycemic clamp
experiment. In the basal state, Mstn
2/2 mice had significantly
reduced plasma glucose (Fig. 3A) and insulin levels
(189652 pmol/L in Mstn
2/2 mice vs. 361669 pmol/L in
Mstn
+/+ mice, P=0.018). Basal glucose turnover, however, was
not significantly different between genotypes (89621 mmol/kg/
minute in Mstn
2/2 mice vs. 103615 mmol/kg/minute in Mstn
+/+
mice). During the clamp, although insulin levels were raised to
,688 pmol/L in both strains, the glucose infusion rate (GIR)
required to maintain normal glycemia was 181% higher in Mstn
2/2
mice than in Mstn
+/+ mice indicating that overall insulin sensitivity
was improved in the mutant mice (Fig. 3B). Under the clamp
conditions used, endogenous glucose production was completely
suppressed in both genotypes (data not shown). Whole body glucose
uptake in Mstn
2/2 mice was significantly higher (Fig. 3C), and the
increase in skeletal muscle glucose uptake was nearly significant
(Fig. 3D, P=0.053). Glucose uptake was also increased in adipose
tissue of Mstn
2/2 mice, particularly white adipose tissue (Fig. 3E
and F). This result may be at least partially due to an increase in cell
number per gram of fat pad because of smaller adipocyte size (Fig.
S2). These results demonstrate that Mstn
2/2 mice have greatly
improved whole body glucose uptake in response to insulin even on
standard chow.
The increase in glucose uptake in muscle and adipose tissues
during the clamp suggests these tissues in Mstn
2/2 mice may have
enhanced insulin signaling. We injected insulin into fasted mice
and assessed activation of the insulin signaling pathway by
Western blot (Fig. 4). Insulin signaling normally increases the
phosphorylation of Akt as seen in muscle from Mstn
+/+ mice. In
muscle from Mstn
2/2 mice, the level of phosphorylated Akt was
higher than in Mstn
+/+ mice in response to insulin. Similarly, Akt
was also activated to a greater extent in response to insulin in
WAT and BAT from Mstn
2/2 mice compared to control mice
demonstrating enhanced in vivo insulin signaling in mutant
skeletal muscle and adipose tissues.
Tissue-specific inhibition of myostatin signaling
The metabolic changes we found in Mstn
2/2 mice could be due
to the loss of myostatin signaling in adipose tissue as well as skeletal
muscle. To determine whether inhibition of myostatin signaling in
adipose tissue alters adipose tissue mass and glucose metabolism
independent of increased skeletal muscle mass, we generated a
transgenic mouse line expressing a dominant negative (DN) Acvr2b
gene specifically in adipocytes. An aP2 (fatty acid binding protein
4) promoter fragment, previously used to control expression of
transgenes in differentiated adipocytes [32], was inserted upstream
Figure 2. Mstn
2/2 mice have increased insulin sensitivity and reduced weight gain on standard chow and HFD. (A) Blood glucose levels
during GTT of Mstn
+/+ and Mstn
2/2 mice on standard chow or HFD. n=8–16. (B) Percent of starting glucose during ITT of Mstn
+/+ and Mstn
2/2 mice
on standard chow or HFD. n=6–10. (C) Blood glucose (left panel) and insulin (right panel) 0 and 30 minutes after glucose injection in fasted mice
maintained on standard chow. n=6.(D) Body weight gained by Mstn
+/+ and Mstn
2/2 mice after 10 weeks on diets. n=7–16. *P,0.05, **P,0.01,
***P,0.001. A and B, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on standard chow; above
curves, mice on HFD.
doi:10.1371/journal.pone.0004937.g002
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binding and transmembrane domains without the intracellular
kinase domain (Fig. 5A). This construct was used for pronuclear
injections. Northern blot analysis of RNA from tissues obtained
from mice expressing the adipose-specific dominant negative
transgene (fat-DN) showed high transgene expression in white and
brown adipose tissue (Fig. 5B). A low level of transgene expression
was detectable in skeletal muscle either from leaky transgene
expression in muscle cells or possibly from intermuscular
adipocytes. Heart tissue similarly had low transgene expression.
No signal was detectable in brain, liver, kidney, and testes (Fig. 5B
and data not shown).
We compared fat-DN mice to mice expressing the same
dominant negative receptor specifically in skeletal muscle (muscle-
DN) which have an increase in muscle mass comparable to Mstn
2/2
mice [33]. We detected some expression of the transgene in BAT in
muscle-DN mice (Fig. S3). This expression, however, was consider-
ably lower than the expression of the transgene in muscle-DN skeletal
muscle or in fat-DN BAT (Fig. S3 and 5B). Both the fat-DN and
muscle-DN mice, unlike Mstn
2/2 mice, still secrete myostatin into
circulation(datanotshown).Wefirstmeasuredbodycomposition in
each line to determine whether fat mass was affected by these
transgenes. We did not detect any differences in body composition
in fat-DN mice compared to controls (Fig. 5C) although transgenic
mice tended to have higher body weight at older ages (data not
shown). By histology, the adipocyte cell sizes were similar between
fat-DN and non-transgenic littermates (Fig. S2). In contrast, muscle-
DN mice, like Mstn
2/2 mice, had an increase in lean mass and a
decrease in fat mass compared to non-transgenic littermates
(Fig. 5D). Despite having intact myostatin signaling in adipose
tissue, muscle-DN mice had smaller adipocytes than control
littermates, as did Mstn
2/2 mice (Fig. S2).
These results suggest that the decrease in fat mass in Mstn
2/2
mice is an indirect effect of increased muscle mass or loss of
myostatin signaling in muscle rather than a direct effect of the loss
of myostatin signaling in adipose tissue. It is possible, however, that
a role for myostatin and/or Acvr2b in regulating adipose tissue
size might only be seen under conditions that lead to increased
adiposity. To test this hypothesis, mice from both transgenic lines
were placed on HFD. After 10 weeks, there was no difference in
body weight gained between fat-DN mice and non-transgenic
littermates on standard chow or HFD (Fig. 5E). Liver triglyceride
concentrations were also similar between fat-DN and control mice
on both diets (Table S2). Furthermore, there was little or no
difference in glucose or insulin tolerance between fat-DN and
Figure 3. Mstn
2/2 mice have increased glucose uptake by hyperinsulinemic-euglycemic clamp. (A) Plasma glucose concentration before
and during clamp. Insulin was infused at time 0. (B) Glucose infusion rate during clamp. Glucose uptake in (C) whole body, (D) skeletal muscle, (E)
WAT, and (F) BAT. n=7–8. *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0004937.g003
Figure 4. Insulin-stimulated activation of Akt by Western blot.
In vivo total Akt and phospho-Akt in gastrocnemius muscle, WAT, and
BAT from Mstn
+/+ and Mstn
2/2 mice with or without insulin stimulation.
Each lane contains protein from a different animal.
doi:10.1371/journal.pone.0004937.g004
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myostatin inhibition in adipocytes does not affect whole body
glucose metabolism under these conditions.
We also measured adipokines and other serum parameters. Fat-
DN mice had lower circulating free fatty acid levels than control
mice on standard chow (Table 1). Serum resistin was higher in fat-
DN mice which was significant in mice on HFD. These results
suggest that myostatin and/or other Acvr2b-binding ligands may
have a role in adipocyte function. All other values were not
significantly different from control mice.
In contrast to fat-DN mice, muscle-DN mice were resistant to weight
gain due to diet-induced obesity and did not gain more weight on
HFD than on standard chow (Fig. 5F) similar to Mstn
2/2 mice
(Fig. 2D). Muscle-DN mice also had improved glucose and insulin
tolerancecompared tocontrols onboth diets(Fig. 5Hand J).Muscle-
DN mice had lower insulin and leptin levels compared to littermate
control mice, which were significant on HFD (Table 1). Muscle-DN
mice also had lower serum triglyceride and FFA levels on standard
chow and tended to have lower liver triglyceride concentrations
compared to control mice on both diets (Table S2). Overall, these
results demonstrate that muscle-DN mice have a similar metabolic
profile to Mstn
2/2 mice, and that inhibition of myostatin signaling
specifically in skeletal muscle, but not adipose tissue, results in
reduced adipose tissue mass and ameliorates the consequences of
diet-induced obesity.
Adaptation to increased muscle mass in Mstn
2/2 mice
We next asked whether Mstn
2/2 mice have similar metabolic
responses to increased muscle mass as HFD-fed mice expressing a
muscle-specific inducible constitutively active Akt1 transgene. First,
Figure 5. Tissue-specific inhibition of myostatin signaling. (A) Diagram of the construct used to make fat-DN transgenic mice with the aP2
promoter controlling expression of a truncated Acvr2b containing the extracellular ligand binding and transmembrane domains. (B) Northern blot
analysis of expression of fat-DN transgene and Gapdh loading control from different tissues from non-transgenic (2) and transgenic (+) mice. Body
composition of (C) fat-DN (n=10–11) and (D) muscle-DN (n=5) male mice compared to non-transgenic littermates. Lean and fat mass are shown as
absolute values. Body weight gained by (E) fat-DN (n=9–17) and (F) muscle-DN (n=9–14) male mice and littermate controls after 10 weeks on diets.
Blood glucose levels during GTT of (G) fat-DN (n=7–8) and (H) muscle-DN (n=9–14) male mice and littermate controls on standard chow and HFD.
Percent of starting glucose during ITT of (I) fat-DN (n=7–8) and (J) muscle-DN (n=9–12) male mice and littermate controls on standard chow and
HFD. *P,0.05, **P,0.01, ***P,0.001. G–J, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on
standard chow; above curves, mice on HFD.
doi:10.1371/journal.pone.0004937.g005
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2/2 mice for evidence of an increase in
gluconeogenesis and glycolysis relative to control mice. Constitu-
tively active Akt1 mice have an increase in expression in liver of
genes encoding enzymes involved in gluconeogenesis, phospho-
enolpyruvate carboxykinase (Pepck) and glucose 6-phosphatase
(G6Pase), and an increase in serum levels of glucagon, which
stimulates gluconeogenesis [29]. We found an increase in
expression of Pepck in the liver of Mstn
2/2 mice relative to control
littermates on standard chow but not HFD (Fig. 6A). The
expression of Pepck in Mstn
+/+ mice on HFD was significantly
higher than in Mstn
+/+ mice on standard chow (Fig. 6A). Mstn
2/2
mice, however, did not have increased expression of Pepck when
fed a HFD relative to standard chow (Fig. 6A). There was no
statistically significant difference in the expression of G6Pase in
liver between genotypes on either diet although the level of G6Pase
expression appeared to be higher in Mstn
2/2 mice than in controls
on standard chow (Fig. 6A). Furthermore, there was no difference
in serum glucagon levels between Mstn
+/+ and Mstn
2/2 mice on
standard chow or HFD (Fig. 6B) or in basal endogenous glucose
production on standard chow as measured prior to insulin infusion
during the hyperinsulinemic-euglycemic clamp experiment
(89621 mmol/kg/minute in Mstn
2/2 mice vs. 103615 mmol/
kg/minute in Mstn
+/+ mice). Constitutively active Akt1 transgenic
mice fed a HFD also have an increase in serum lactate levels, the
end product of anaerobic glycolysis, but Mstn
2/2 mice did not
have increased serum lactate levels compared to Mstn
+/+ mice on
either diet (Fig. 6C).
We next looked for evidence of altered metabolism of fatty acids
in the liver. Mstn
2/2 mice have a lower concentration of liver
triglycerides than Mstn
+/+ mice on both diets (Table S2). The
expression of liver carnitine palmitoyl transferase-1 (Cpt1), an
enzyme required for fatty acid import into mitochondria, and
medium chain acyl-Coenzyme A dehydrogenase (Acadm, also
known as Mcad and Acad1), an enzyme that metabolizes medium
chain fatty acids, are increased in liver from HFD-fed constitu-
tively active Akt1 mice [29]. We found a non-significant increase in
expression of Cpt1 in Mstn
2/2 mice compared to Mstn
+/+ mice on
standard chow (P=0.085), but there were no differences in
expression of Acadm between genotypes on either diet (P=0.321 on
standard chow and P=0.161 on HFD) (Fig. 6A). Constitutively
active Akt1 transgenic mice on HFD also have higher serum ketone
levels indicating increased fatty acid oxidation by the liver [29].
We therefore measured the concentration of the ketone b-
hydroxybutyrate in serum from Mstn
+/+ and Mstn
2/2 mice on
standard chow and HFD. There was no increase in b-
hydroxybutyrate levels in Mstn
2/2 mice on either diet compared
to control mice (Fig. 6D). Finally, the expression of stearoyl-
Coenzyme A desaturase 1 (Scd1), which catalyzes the conversion of
saturated fatty acids to monounsaturated fatty acids, is decreased
in the liver of constitutively active Akt1 transgenic mice on HFD
reflecting a reduction in lipid synthesis. We did not find any
difference in expression of Scd1 between Mstn
+/+ and Mstn
2/2
mice on either diet (Fig. 6A). These results demonstrate that the
response to diet-induced obesity is different between Mstn
2/2 mice
and constitutively active Akt1 mice.
Discussion
Our results show that Mstn
2/2 mice have improved glucose
metabolism and increased insulin sensitivity on both standard
chow and high fat diet. We also show that the changes in glucose
metabolism and adiposity are a consequence of alteration of
skeletal muscle rather than a direct effect of the inhibition of
myostatin signaling in adipose tissue. Although the adipocyte- and
muscle-expressed transgenes showed faint expression in muscle
and adipose tissue, respectively, the phenotypes of the mice were
very different. Thus, it is unlikely that the leaky expression
accounts for the phenotypes presented here.
Like transgenic mice overexpressing myostatin in adipose tissue
[22], inhibition of Acvr2b function in adipocytes did not alter body
composition. Taken together, the data suggest that the loss of
adipose tissue in mice with high serum myostatin caused by a
myostatin-secreting tumor [24] required supraphysiologic levels of
myostatin. Because the aP2 promoter we used to express the
dominant negative receptor is expressed relatively late in
adipogenesis, it remains possible that inhibition of myostatin
signaling in very early stage progenitors would have an effect on
overall adipose mass. This may be unlikely because, in adipose-
Figure 6. Adaptation to increased muscle mass. (A) Relative mRNA expression levels in liver of Pepck, G6Pase, Cpt1, Acadm, and Scd1 measured
by quantitative RT-PCR in Mstn
+/+ and Mstn
2/2 mice on standard chow or HFD. (B) Serum glucagon, (C) lactate, and (D) b-hydroxybutyrate levels in
Mstn
+/+ and Mstn
2/2 mice on standard chow and HFD. n=6–12. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0004937.g006
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detected even though myostatin secreted by mature adipocytes
would in theory be capable of signaling on uncommitted and
undifferentiated progenitors within the fat pad [22]. It is also
possible that, although Acvr2b inhibition in skeletal muscle
phenocopies Mstn deletion, multiple ligands with opposite rather
than redundant functions bind Acvr2b in mature adipocytes
blunting an effect of inhibition of myostatin alone.
The decrease in serum free fatty acid levels in fat-DN mice
suggests some function for myostatin and/or other Acvr2b-binding
ligands in mature adipocytes. However, we and others were not
able to see any change in the rate of lipolysis in adipocytes in vitro
in response to myostatin [26], and data not shown]. Other
metabolic challenges to fat-DN mice may reveal specific functions
for Acvr2b ligands in adipocytes.
Given our results presented here and the reduction in adiposity
in transgenic mice with increased muscularity caused by changes
in other signaling pathways such as IGFI [28,29,30,31], we
hypothesize that the decrease in adipose tissue size in Mstn
2/2 and
muscle-DN mice is most likely an indirect result of the increased
muscle mass. It is also possible the myostatin signaling pathway
might have a direct role in regulating muscle metabolism that
consequently affects adipose tissue mass separate from its role in
regulating muscle mass. In this regard, some in vitro studies have
suggested a role for myostatin in regulation of Akt activation. For
example, myostatin has been shown to inhibit activation of Akt in
phenylephrine-treated cardiomyocytes [34] and reduce the basal
level of phosphorylated Akt in C2C12 myotubes [35]. Myostatin
also reduces the level of Akt activation in C2C12 undifferentiated
myoblasts engineered to overexpress Akt [36]. In contrast,
myostatin increases basal glucose uptake in human placental
extracts [37]. It will be important to examine other signaling
pathways in myostatin-deficient skeletal muscle that might regulate
metabolism to determine whether the improved metabolism is due
to increased muscle mass, the loss of myostatin signaling, or both.
Another plausible explanation for reduced adipose tissue mass
in muscular mice is ‘‘substrate steal’’ by skeletal muscle [38]. If
skeletal muscle has increased glucose uptake, fewer carbohydrates
would be available as substrates for liver triglyceride synthesis and
subsequent storage in adipocytes. In this regard, induction of
constitutively active Akt1 caused fast glycolytic fiber hypertrophy in
mice on HFD, an increase in glucose uptake into muscle, and an
increase in lipid oxidation in liver [29]. Mstn
2/2 mice also have
fiber hypertrophy in muscles comprised of predominantly fast
glycolytic fibers [16,39]. In addition, Mstn
2/2 mice are consider-
ably more muscular than constitutively active Akt1 mice, have a
higher number of fast glycolytic fibers [8,16], and have less adipose
mass even on standard chow [17,18]. It might therefore be
expected that deletion of the Mstn gene would result in even more
dramatic effects on liver metabolism. We did not find this to be the
case although the gene expression data from liver from Mstn
2/2
mice fed a standard chow suggest a slight trend toward reduced
lipogenesis, increased gluconeogenesis, and increased lipid oxida-
tion (Fig. 6). This trend was not, however, seen in liver from mice
fed a HFD unlike in constitutively active Akt1-expressing mice fed
a HFD [29]. Furthermore, consistent with our data, Stolz et al
[26] found no difference in the rate of fatty acid oxidation in the
liver of Mstn
2/2 mice fed standard chow.
There are several differences between the constitutively active
Akt1 and Mstn
2/2 mouse models which might explain why these
two muscular mutants did not have the same changes in liver gene
expression and in serum values when fed a HFD. By approxi-
mately weaning age, Mstn
2/2 mice are more muscular than
Mstn
+/+ mice due to both hypertrophy and hyperplasia of muscle
fibers. In contrast, constitutively active Akt1 transgenic mice gain
muscle due to hypertrophy of existing fibers only after transgene
induction in adulthood. More subtle compensatory metabolic
changes could already have occurred in Mstn
2/2 mice in prenatal
or early postnatal life. Furthermore, the altered signaling pathways
that result in muscle hypertrophy are different in each model.
Basal levels of activated Akt are high in constitutively active Akt1
transgenic muscle [29], but not in Mstn
2/2 muscle (Fig. 4).
Consequently, signaling to other tissues by myokines or muscle
metabolites may be different. Like induction of constitutively
active Akt1, postnatal inhibition of myostatin signaling in mice
causes fiber hypertrophy without hyperplasia or change in fiber
composition [8,9]. Postnatal inhibition of myostatin signaling in
mice with diet-induced obesity will be necessary to directly
compare these two muscle hypertrophy models to determine
whether the reduction in adipose tissue mass in HFD-fed
constitutively active Akt1 mice is caused by hypertrophy of fast
glycolytic fibers, by increasing the activation of the Akt signaling
pathways, or both.
Injection of a myostatin neutralizing monoclonal antibody in
mice on standard chow, however, does not cause a reduction in
adipose tissue mass even though the weight of individual muscles is
increased 20–30% [9]. Similarly, a milder increase in muscle mass
caused by injection of the same monoclonal antibody in the
extremely obese leptin receptor-deficient mice does not reduce
adipose tissue mass [26]. Mice null for both Mstn and leptin have a
mild decrease in adipose tissue compared to leptin null mice, but
this improvement is found only in young animals [18]. These
results suggest that mice deficient in leptin signaling might be too
obese to be rescued by muscle hypertrophy after the onset of
obesity. Treatment of mice that are obese due to different genetic
or dietary causes with myostatin antagonists will clarify which, if
any, specific types of obesity are rescued by postnatal inhibition of
myostatin. Additionally, varying the degree of muscle hypertrophy
by treatment with different doses of myostatin antagonists will help
determine whether there is a threshold level of hypertrophy
required for a reduction in obesity.
In addition to the potential for reducing adiposity, we believe
that the improved insulin sensitivity in Mstn
2/2, muscle-DN, and
constitutively active Akt1 mice suggests that altering metabolism by
increasing muscle mass might be a promising strategy for treating
diabetes and the metabolic syndrome. Skeletal muscle of diabetics
has reduced insulin sensitivity [40], and recent clinical trials
suggest that resistance training improves insulin sensitivity in
diabetic patients [41,42]. Similar to the muscle phenotype caused
by postnatal myostatin inhibition or inducible constitutively active
Akt expression [1,2,29], resistance exercise causes an increase in
fiber size [43]. Some studies have shown, however, that resistance
training in humans can also cause shifts in fiber type not seen in
these mouse models of postnatal muscle hypertrophy, and mouse
muscle contains relatively more fast fibers than human muscle
[43]. Nevertheless, it is possible that increasing muscle mass by
pharmacologic interventions such as inhibiting myostatin signaling
may improve glucose metabolism in diabetics, particularly those in
poor physical condition who are unable to perform resistance
exercise.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the Animal
Care and Use Committee of the NIDDK, NIH.
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Generation N6 Mstn
+/+ and Mstn
2/2 mice [16] in the C57BL/
6Ncr genetic background were obtained from homozygous
matings for all experiments except diet experiments in which N6
Mstn
+/+ and Mstn
2/2 mice were obtained from heterozygous
matings. Mstn genotypes were determined by PCR as described
[44]. The muscle-specific dominant negative Acvr2b transgenic
line, C11, in the C57BL6/Ncr genetic background (.N10) has
been previously described [33]. Muscle-DN mice were genotyped
by PCR (forward, 59-CCATTTATAGTCTGAGCCCGAATG-
CC-39; reverse, 59-AATTGAAGTCATCTAGCCAGCAGCCC-
39; 500 bp). For generation of adipose-specific dominant negative
Acvr2b transgenic mice, the same truncated mouse Acvr2b coding
sequence which was used for generation of line C11 (amino acids 1–
174) was inserted into the PstI site of KS/422-Flag Ø10 3heptad-F/
splice aP2 promoter vector [32] after removal of the Ø10 3heptad-F
insert. Founders in the FVB genetic background were backcrossed to
C57BL/6Ncratleast5timestogenerateanimalsforexperimentsand
were genotyped by PCR (forward, 59-GCTGCTGCGAAGG-
CAACTTCTGCAACGAG -39;r e v e r s e ,5 9-CTCTGTAGG-
TAGTTTGTCCAATTATGTC-39; 341 bp). Non-transgenic litter-
mates were used as controls for both transgenic lines. Mice were fed
ad lib and kept under a 12-hour light/dark cycle.
Metabolic analyses
Hyperinsulinemic-euglycemic clamps were performed in awake
mice fasted for 5 hour as previously described [45] with
modifications. Experiments used primed-continuous infusion of
[3-
3H] glucose (2.5 mCi bolus, 0.05 mCi/minute during the basal
state, and 0.1 mCi/minute during the clamp period). Insulin was
infused at the rate of 2.5 mU/kg/minute (without bolus). Indirect
calorimetry and activity measurements were performed as
described [46]. Lipid oxidation was carried out on conscious
animals [47] and on isolated soleus muscle [45] as described. Body
composition of 5–7 month old animals was measured using the
EchoMRI 3-in-1
TM (Echo Medical Systems).
High-fat diet treatment and analysis
Nine week old males were fed either standard chow (NIH-31
Open Formula, Zeigler) or a 4.73 kcal/g HFD with 45% kcal
from fat and 35% kcal from carbohydrates (D12451, Research
Diets) for 10 weeks. GTT and ITT were performed after 8 and 9
weeks, respectively (see below). After 10 weeks, fed animals were
anesthetized by i.p. injection of 80 mg/kg BW pentobarbital, and
serum samples were collected by cardiac puncture. Liver and
adipose samples were quickly frozen on dry ice or put in RNA
Later (Ambion) for protein and RNA analysis.
Glucose tolerance and insulin tolerance tests
GTT and ITT were performed as described [20]. Blood glucose
was measuredby tailbleeding at indicatedtime points usingan Elite
Glucometer (Bayer). Blood from tail tips of fasted mice was taken
before and 30 minutes after injection of 2 mg/kg BW glucose for
measurements of serum insulin during glucose challenge.
RNA isolation, Northern blotting, and quantitative RT-
PCR
Total RNA was isolated from tissues using Trizol Reagent
(Invitrogen) according to the manufacturer’s instructions. For
Northern analysis, 20 mg total RNA was used for electrophoresis
and blotting to GeneScreen Plus membrane (Perkin Elmer) and
hybridized according to the manufacturer’s instructions with a
probe corresponding to the extracellular region of mouse Acvr2b.
For real-time quantitative PCR, samples were digested with
DNase followed by reverse transcription of 500 ng total RNA
using Superscript II (Invitrogen). The resulting cDNA was
quantified by real-time quantitative PCR on an ABI PrismH
7000 Sequence Detection System using indicated Taqman primers
(Applied Biosystems) and normalized to 18S expression.
Serum measurements
Serum insulin, leptin, resistin, and glucagon were determined by
radioimmunoassay (Millipore). Serum triglycerides (Infinity tri-
glycerides kit, Thermo), free fatty acids (half micro test kit, Roche),
b-hydroxybutyrate (Stanbio Laboratory), and lactate (BioVision)
were determined by colorimetric methods according to the
manufacturer’s instructions.
Phospho-Akt detection
For in vivo Akt detection, mice were fasted overnight,
anesthetized with pentobarbital (80 mg/kg body weight), and
injected i.p. with 10 U/kg BW insulin (Lilly). Gastrocnemius
muscle, gonadal WAT and intrascapular BAT were removed after
10 minutes and frozen in a dry ice ethanol bath, homogenized in
RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM sodium chloride, 1 mM EDTA) contain-
ing 1 mM sodium orthovanadate, 1 mM sodium fluoride, and
proteinase inhibitor cocktail (Roche), and centrifuged at 13,000 g
for 10 minutes to collect supernatants. Supernatants (20 mg
protein) were used for reducing SDS PAGE and Western blotting.
For immunoblotting analysis of phospho-Akt, Western blots were
incubated with a 1:2000 dilution of rabbit anti-phospho-Akt-
Ser473 (Cell Signaling), followed by a 1:5000 dilution of HRP-
conjugated goat anti-rabbit secondary antibody (Invitrogen), and
detected by ECL (Pierce). Blots were then stripped (H2O, 0.2N
sodium hydroxide, H2O, for 5 minutes each) and incubated with a
1:2000 dilution of rabbit anti-Akt primary antibody (Cell
Signaling) followed by detection as above to detect total Akt.
Liver triglyceride measurements
Extraction of tissue triglycerides with chloroform/methanol was
modified from Burant et al [48]. After hydrolysis with 200 mLo f
3 M potassium hydroxide in 65% ethanol, triglycerides were
measured radiometrically using a glycerol kinase assay [49].
Histology
Tissues were dissected, fixed in 10% formalin, dehydrated,
embedded in paraffin, sectioned, and stained with H&E.
Statistical analysis
Results are expressed as mean6SEM. Statistical analysis of the
hyperinsulinemic-euglycemic clamp data for increases in glucose
infusion rate and glucose uptake in Mstn
2/2 mice was performed
using one-tailed student’s t test. Statistical analysis of data from
HFD experiments, except GTT and ITT, was performed using
SPSS software by two-factor ANOVA with genotype and diet as
the factors. When between-subjects effects were significant, data
were further analyzed by pairwise comparisons using Bonferroni
confidence interval adjustment for multiple comparisons. Indirect
calorimetry, GTT, and ITT data were analyzed by 2-tailed
student’s t test. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 Fat pad mass of Mstn+/+ and Mstn2/2 mice on
standard chow or HFD.
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Figure S2 Representative images of H&E stained gonadal fat
pads from mutant mice and control littermates on standard chow
or high fat diet (HFD).
Found at: doi:10.1371/journal.pone.0004937.s002 (0.99 MB
PDF)
Figure S3 Northern blot analysis of expression of muscle-DN
transgene and Gapdh loading control from non-transgenic (2) and
transgenic (+) mice.
Found at: doi:10.1371/journal.pone.0004937.s003 (0.12 MB
PDF)
Table S1 Indirect calorimetry
Found at: doi:10.1371/journal.pone.0004937.s004 (0.05 MB
PDF)
Table S2 Liver triglyceride concentration on standard or HFD
Found at: doi:10.1371/journal.pone.0004937.s005 (0.11 MB
PDF)
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